Gossamer Bio Ausschüttungen und Rückkäufe

Zukünftiges Wachstum Kriterienprüfungen 0/6

Gossamer Bio hat in der Vergangenheit keine Dividende gezahlt.

Wichtige Informationen

n/a

Dividendenausschüttung

-0.4%

Rückkaufsrendite

Gesamte Aktionärsrendite	-0.4%
Zukünftige Dividendenrendite	0%
Wachstum der Dividende	n/a
Nächster Dividendenzahlungstermin	n/a
Ex-Dividendendatum	n/a
Dividende pro Aktie	n/a
Ausschüttungsquote	n/a

Jüngste Updates zu Dividenden und Rückkäufen

Keine Aktualisierungen

Recent updates

Gossamer Bio Has One More Shot On Goal And Is Not Likely To Miss

Sep 10

Brokers Are Upgrading Their Views On Gossamer Bio, Inc. (NASDAQ:GOSS) With These New Forecasts

Aug 14

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von GOSS in der Vergangenheit stabil war.

Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von GOSS gestiegen sind.

Dividendenrendite im Vergleich zum Markt

Gossamer Bio Dividendenrendite im Vergleich zum Markt

Wie sieht die Dividendenrendite von GOSS im Vergleich zum Markt aus?
Segment	Dividendenrendite
Unternehmen (GOSS)	n/a
Untere 25 % des Marktes (US)	1.3%
Markt Top 25 % (US)	4.2%
Branchendurchschnitt (Biotechs)	2.3%
Analystenprognose (GOSS) (bis zu 3 Jahre)	0%

Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von GOSS im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von GOSS im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von GOSS, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.

Barausschüttung an die Aktionäre

Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da GOSS keine Ausschüttungen gemeldet hat.

Gossamer Bio Ausschüttungen und Rückkäufe

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Updates zu Dividenden und Rückkäufen

Recent updates

Gossamer Bio Receives Written Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement

Gossamer Bio Has One More Shot On Goal And Is Not Likely To Miss

Consensus revenue estimates increase by 17%

Brokers Are Upgrading Their Views On Gossamer Bio, Inc. (NASDAQ:GOSS) With These New Forecasts

New major risk - Share price stability

Price target increased by 12% to US$6.42

COO & CFO recently bought US$59k worth of stock

Gossamer Bio, Inc. Receives A Written Notice from the Staff Regarding Minimum Bid Price Requirement

Gossamer Bio, Inc., Annual General Meeting, Jun 06, 2024

Gossamer Bio Announces Board of Directors Appointments

Price target increased by 15% to US$6.09

Gossamer Bio Inc. Appoints Bob Smith as Chief Commercial Officer

Gossamer Bio, Inc. Appoints John Quisel to Its Board of Directors

Gossamer Bio, Inc. Appoints John Quisel to Its Board of Directors

COO & CFO recently bought US$113k worth of stock

Gossamer Bio Receives Non-Compliance Notice from Nasdaq

Gossamer Bio Receives Non-Compliance Notice from Nasdaq

Gossamer Bio, Inc. Announces Resignation of Kristina Burow from the Board of Directors

Price target decreased by 13% to US$5.18

Price target decreased by 7.9% to US$5.85

Gossamer Bio, Inc. announced that it has received $211.849524 million in funding from a group of investors

New major risk - Shareholder dilution

New major risk - Share price stability

Price target decreased by 7.2% to US$7.05

Price target increased by 14% to US$8.20

Gossamer Bio, Inc., Annual General Meeting, Jun 08, 2023

COO & CFO recently bought US$56k worth of stock

Co-Founder recently bought US$1.0m worth of stock

Price target decreased to US$13.00

Gossamer Bio, Inc. Announces Seralutinib Meets Primary Endpoint in Phase 2 Torrey Study in PAH

Insufficient new directors

Chief Scientific Officer recently sold US$59k worth of stock

Peaking Back In On Gossamer Bio

Price target increased to US$18.64

Price target increased to US$18.10

Price target increased to US$17.60

Gossamer Bio, Inc. announced that it has received $120.041922 million in funding from a group of investors

Gossamer Bio, Inc. announced that it expects to receive $120.041922 million in funding from a group of investors

Gossamer Bio to raise $120M in a private equity placement

Chief Scientific Officer recently sold US$73k worth of stock

Health Check: How Prudently Does Gossamer Bio (NASDAQ:GOSS) Use Debt?

Price target decreased to US$15.80

Insufficient new directors

Gossamer Bio, Inc. Announces Topline Results from its Phase 2 SHIFT-UC Study Clinical Trial Studying GB004 in Patients

Co-Founder recently sold US$170k worth of stock

Insider recently sold US$52k worth of stock

Insider recently sold US$52k worth of stock

Insider recently sold US$52k worth of stock

Gossamer Bio, Inc. to Report Q4, 2021 Results on Mar 03, 2022

Gossamer Bio (NASDAQ:GOSS) Has Debt But No Earnings; Should You Worry?

Price target increased to US$21.25

Insufficient new directors

Price target increased to US$19.50

Is Gossamer Bio (NASDAQ:GOSS) A Risky Investment?

Price target decreased to US$19.00

Gossamer Bio, Inc.(NasdaqGS:GOSS) dropped from Russell 2500 Growth Index

Chief Scientific Officer has left the company

Chief Scientific Officer recently sold US$52k worth of stock

Chief Scientific Officer recently sold US$52k worth of stock

Gossamer Bio, Inc. to Report Q4, 2020 Results on Feb 25, 2021

Need To Know: Gossamer Bio, Inc. (NASDAQ:GOSS) Insiders Have Been Buying Shares

Gossamer Bio, Inc. Announces Executive Changes

Gossamer Bio (GOSS) Investor Presentation - Slideshow

Gossamer Bio Announces Appointment of Faheem Hasnain as Chief Executive Officer

Gossamer Bio, Inc. Provides Clinical-Stage Product Candidate Updates

Gossamer Bio, Inc. to Report Q3, 2020 Results on Nov 10, 2020

New 90-day low: US$8.93

Co-Founder & Chairman recently bought US$1m worth of stock

Gossamer Bio, Inc. Announces Topline Results for Phase 2 Trials of Oral GB001 in Asthma and Chronic Rhinosinusitis

Price target lowered to US$26.13

New 90-day low: US$10.09

Gossamer Bio Announces Presentation of GB004 Phase 1b Clinical Data at United European Gastroenterology Virtual Week 2020 and Additional Program Updates

New 90-day low: US$11.30

Stabilität und Wachstum des Zahlungsverkehrs

Dividendenrendite im Vergleich zum Markt